Evidence map›Paper›PMID 37056364›Full record

ArticleFrontiers in neurology2023

The Gut Dysmotility Questionnaire for Parkinson's disease: Insights into development and pretest studies.

Vanessa Raeder, Lucia Batzu, Robert Untucht, Annekathrin Fehre, Alexandra Rizos, Valentina Leta, Renate Schmelz, Jochen Hampe, Sevasti Bostantjopoulou, Zoe Katsarou and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

Vanessa RaederDepartment of Neurology, University Hospital Dresden, Technische Universität Dresden, Dresden, Germany.
Lucia BatzuParkinson's Foundation Centre of Excellence, King's College Hospital, London, United Kingdom.
Robert UntuchtDepartment of Neurology, University Hospital Dresden, Technische Universität Dresden, Dresden, Germany.
Annekathrin FehreDepartment of Neurology, Elblandklinikum Meißen, Meißen, Germany.
Alexandra RizosParkinson's Foundation Centre of Excellence, King's College Hospital, London, United Kingdom.
Valentina LetaParkinson's Foundation Centre of Excellence, King's College Hospital, London, United Kingdom.
Renate SchmelzDepartment of Internal Medicine I, University Hospital Dresden, Technische Universität Dresden, Dresden, Germany.
Jochen HampeDepartment of Internal Medicine I, University Hospital Dresden, Technische Universität Dresden, Dresden, Germany.
Sevasti Bostantjopoulou3rd Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Zoe Katsarou3rd Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Alexander StorchDepartment of Neurology, University of Rostock, Rostock, Germany.
Heinz ReichmannDepartment of Neurology, University Hospital Dresden, Technische Universität Dresden, Dresden, Germany.
Björn FalkenburgerDepartment of Neurology, University Hospital Dresden, Technische Universität Dresden, Dresden, Germany.
K Ray ChaudhuriParkinson's Foundation Centre of Excellence, King's College Hospital, London, United Kingdom.
Lisa KlingelhoeferDepartment of Neurology, University Hospital Dresden, Technische Universität Dresden, Dresden, Germany.
Technische Universität Dresden · DEKing's College Hospital · GBAristotle University of Thessaloniki · GRKing's College London · GBUniversity of Rostock · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: A total of 48% of patients with Parkinson's disease (PD) present symptoms of gastrointestinal dysfunction, particularly constipation. Furthermore, gastrointestinal tract (GIT)-related non-motor symptoms (NMSs) appear at all stages of PD, can be prodromal by many years and have a relevant impact on the quality of life. There is a lack of GIT-focused validated tools specific to PD to assess their occurrence, progress, and response to treatment. The aim of this study was to develop and evaluate a novel, disease- and symptom-specific, self-completed questionnaire, titled Gut Dysmotility Questionnaire (GDQ), for screening and monitoring gastrointestinal dysmotility of the lower GIT in patients with PD. Methods: In phase 1, a systematic literature review and multidisciplinary expert discussions were conducted. In phase 2, cognitive pretest studies comprising standard pretests, interviews, and evaluation questionnaires were performed in patients with PD ( Results: We report significantly higher GDQ total scores and higher scores in five out of eight domains indicating a higher prevalence of gastrointestinal dysmotility in patients with PD than in HC ( Interpretation: The GDQ is a novel, easy, and quick 18-item self-assessment questionnaire to screen for and monitor gastrointestinal dysmotility with a focus on constipation in patients with PD. It has shown high acceptance and efficacy as well as good construct validity in cognitive pretests.

Indexed as

bowel movementcognitive pretestconstipationgutnon-motor symptomsParkinson's diseasequestionnaire

Identifiers

PMID37056364
PMCPMC10086186
OpenAlexW4361216978

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.